Results 201 to 210 of about 160,832 (337)

Defining an Unresectable Primary Retroperitoneal Sarcoma

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Retroperitoneal sarcomas (RPS) comprise a heterogenous group of rare mesenchymal tumours. A complete macroscopic en bloc resection of the tumour with involved adjacent structures is the only curative treatment modality. There remain no consensus criteria regarding the definition of a resectable versus unresectable RPS.
James Tai, Eyal Mor, Catherine Mitchell, Kwang Chin, Stephen Schlicht, Hayden Snow, David E. Gyorki   +6 more
wiley   +1 more source

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313). [PDF]

Oncologist
Villaruz LC, Schluger B, Wang H, Ohr J, Petro D, Fuld AD, Herzberg B, Dawar R, Nieva J, Ruiz J, Christner SM, Holleran JL, Bakkenist CJ, Gore S, Beumer JH.   +14 more
europepmc   +1 more source

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

British Journal of Haematology, EarlyView.
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu   +24 more
wiley   +1 more source

Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma. [PDF]

Clin Med Insights Oncol
Bayram D, Efil SC, Türk S, Kara O, Sekmek S, Yücel Ş, Aktürk Esen S, Uçar G, Bal O, Algin E, Uncu D.   +10 more
europepmc   +1 more source

Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine‐based salvage regimens against acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Left: Cells with active SAMHD1 can metabolize cytarabine (ara‐C) and fludarabine (F‐ara‐A) to their inactive precursors, limiting their cytotoxic effects. Right: Addition of hydroxyurea (hydroxycarbamide; HU) inhibits SAMHD1, leading to an increase in the active metabolites of ara‐C and F‐ara‐A and a subsequent increase in the cytotoxicity of these ...
Ingrid Lilienthal, Sijia Tao, Christer Nilsson, Elory Leonard, Runqing Zhang, Agnes L. Sorteberg, Louisa Fredrikson, Ioanna Xagoraris, Shahrzad Shirazi Fard, Nikolaos Tsesmetzis, Vasilios Zachariadis, Huan Cai, Lakshmi Sandhow, Anette Langebäck, Anna Bohlin, Katja Pokrovskaja Tamm, Sofia Bengtzén, Raymond F. Schinazi, Sören Lehmann, Baek Kim, Georgios Z. Rassidakis, Hong Qian, Martin Jädersten, Nikolas Herold   +23 more
wiley   +1 more source

The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. [PDF]

Cell Death Dis
Zhang W, Liu R, Hu J, Wan S, Zou Y, Che T, Zhang J, Chen L, Peng X.   +8 more
europepmc   +1 more source

Novel anticancer combination therapies using replication-selective oncolytic adenoviruses and chemotherapeutics [PDF]

, 2011
Hammarén Busch, Kristina
core   +1 more source

Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer

BJU International, EarlyView.
Objective To report long‐term oncological outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) undergoing bladder‐sparing therapy (BST) after bacillus Calmette–Guérin (BCG) failure. Patients and Methods We retrospectively reviewed patients with HR‐NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure,
Ian M. McElree, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Vignesh T. Packiam, Michael A. O'Donnell   +5 more
wiley   +1 more source

Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study. [PDF]

Discov Oncol
Tunbekici S, Sahin G, Yuksel HC, Acar C, Akın I, Aslanhan H, Iscı M, Kabaoglu C, Bal H, Sakin A, Coskun A, Seyyar M, Dilek MS, Kara M, Solmaz A, Demir T, Zin E, Terzi A, Kus F, Kus IK, Arık Z, Aytac A, Demirkıran Ö, Demir B, Yesil H, Biter S, Koseci T, Bayram E, Unsal A, Ozveren A, Sevınc A, Ozaskın D, Baykara M, Unlu A, Kus A, Karacin C, Yalcıner M, Uyar GC, Sutcuoglu O, Kaplan E, Sakalar T, Sahin E, Emin G, Yıldırım A, Mordag C, Ugurlu I, Hacıbekiroglu I, Tunbekici I, Gursoy P, Sanli UA, Goker E.   +50 more
europepmc   +1 more source

Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers [PDF]

, 2007
Sheryl A. Flanagan, Blaine W. Robinson, Christina M. Krokosky, Donna S. Shewach   +3 more
openalex   +1 more source